查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
SER-109 药物洞察与市场预测：2032 年
市场调查报告书
商品编码
1381081

SER-109 药物洞察与市场预测：2032 年

SER-109 Drug Insight and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 30 Pages | 商品交期: 1-3个工作天内

价格

SER-109 由 Seres Therapeutics 开发，有潜力成为一流的研究性口腔微生物组疗法，以减少艰难梭菌感染的復发。它是基于人类临床发现的本土细菌的多功能联合体，在抗生素后口服给药。

SER-109 是厚壁菌门孢子的纯化版本，通常存在于健康微生物组中，因其在艰难梭菌生命週期和疾病发展中的调节作用而被选择。

未来几年，由于广泛的研究和全球医疗保健支出的增加，艰难梭菌感染市场格局预计将会改变。两家公司正在开发专注于治疗/改善疾病状况、评估挑战并探索可能影响 SER-109 优势的机会的新方法的疗法。预计其他针对艰难梭菌感染的新兴产品将面临与SER-109的激烈市场竞争，并且在不久的将来仿製药新兴疗法的推出预计将对市场产生重大影响。

本报告调查了七个主要国家的SER-109市场，并提供了市场概述、2023年至2032年的销售预测数据、竞争格局和国家趋势。

目录

第一章 报告简介

第二章 SER-109治疗艰难梭菌感染概述

  • 产品详情
  • 临床开发
    • 临床研究
    • 临床试验资讯
    • 安全性和有效性
  • 监管里程碑
  • 其他开发活动
  • 产品概要

第三章 竞争格局（上市治疗）

第四章竞争格局（后期新兴疗法）

第五章 SER-109 市场评估

  • SER-109抗艰难梭菌感染的市场前景
  • 7个主要国家市场分析
    • 七个主要国家抗艰难梭菌感染的 SER-109 市场规模
  • 国家市场分析
    • 美国
    • 德国
    • 英国

第6章SWOT分析

第七章 分析师观点

第8章附录

第九章 DelveInsight服务内容

第10章 免责声明

第 11 章关于 DelveInsight

第 12 章 报告购买选项

Product Code: DIDM1076

“"SER-109 Drug Insight and Market Forecast - 2032" report provides comprehensive insights about SER-109 for clostridium difficile infection (CDI) in the seven major markets. A detailed picture of the SER-109 for clostridium difficile infection in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the SER-109 for clostridium difficile infection. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SER-109 market forecast analysis for clostridium difficile infection in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in clostridium difficile infection.

Drug Summary:

SER-109, being developed by Seres therapeutics, is a potential first-in-class investigational oral microbiome therapeutic designed to reduce the recurrence of CDI. It is a multifunctional consortium of commensal bacteria based on human clinical insights and is to be administered orally following antibiotics.

SER-109 is composed of purified firmicutes spores, normally found in healthy microbiome selected for their modulatory role in the life cycle of C. difficile and disease pathogenesis.

Scope of the Report:

The report provides insights into:

  • A comprehensive product overview including the SER-109 description, mechanism of action, dosage and administration, research and development activities in clostridium difficile infection.
  • Elaborated details on SER-109 regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the SER-109 research and development activities in clostridium difficile infection across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around SER-109.
  • The report contains forecasted sales of SER-109 for clostridium difficile infection till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for clostridium difficile infection.
  • The report also features the SWOT analysis with analyst views for SER-109 in clostridium difficile infection.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SER-109 Analytical Perspective by DelveInsight

In-depth SER-109 Market Assessment

This report provides a detailed market assessment of SER-109 for clostridium difficile infection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

SER-109 Clinical Assessment

The report provides the clinical trials information of SER-109 for clostridium difficile infection covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

  • In the coming years, the market scenario for clostridium difficile infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SER-109 dominance.
  • Other emerging products for clostridium difficile infection are expected to give tough market competition to SER-109 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SER-109 in clostridium difficile infection.
  • Our in-depth analysis of the forecasted sales data of SER-109 from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SER-109 in clostridium difficile infection.

Key Questions:

  • What is the product type, route of administration and mechanism of action of SER-109?
  • What is the clinical trial status of the study related to SER-109 in clostridium difficile infection and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SER-109 development?
  • What are the key designations that have been granted to SER-109 for clostridium difficile infection?
  • What is the forecasted market scenario of SER-109 for clostridium difficile infection?
  • What are the forecasted sales of SER-109 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
  • What are the other emerging products available and how are these giving competition to SER-109 for clostridium difficile infection?
  • Which are the late-stage emerging therapies under development for the treatment of clostridium difficile infection?

Table of Contents

1. Report Introduction

2. SER-109 Overview in Clostridium difficile infection

  • 2.1. Product Detail
  • 2.2. Clinical Development
    • 2.2.1. Clinical studies
    • 2.2.2. Clinical trials information
    • 2.2.3. Safety and efficacy
  • 2.3. Regulatory Milestone
  • 2.4. Other Developmental Activities
  • 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. SER-109 Market Assessment

  • 5.1. Market Outlook of SER-109 in Clostridium difficile infection
  • 5.2. 7MM Analysis
    • 5.2.1. Market Size of SER-109 in the 7MM for Clostridium difficile infection
  • 5.3. Country-wise Market Analysis
    • 5.3.1. Market Size of SER-109 in the United States for Clostridium difficile infection
    • 5.3.2. Market Size of SER-109 in Germany for Clostridium difficile infection
    • 5.3.3. Market Size of SER-109 in France for Clostridium difficile infection
    • 5.3.4. Market Size of SER-109 in Italy for Clostridium difficile infection
    • 5.3.5. Market Size of SER-109 in Spain for Clostridium difficile infection
    • 5.3.6. Market Size of SER-109 in the United Kingdom for Clostridium difficile infection
    • 5.3.7. Market Size of SER-109 in Japan for Clostridium difficile infection

6. SWOT Analysis

7. Analysts' Views

8. Appendix

  • 8.1. Bibliography
  • 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

List of Tables

  • Table 1: SER-109, Clinical Trial Description, 2023
  • Table 2: SER-109, General Description
  • Table 3: Competitive Landscape (Marketed Therapies)
  • Table 4: Competitive Landscape (Emerging Therapies)
  • Table 5: SER-109 Market Size in the 7MM, in USD million (2019-2032)
  • Table 6: SER-109 Market Size in the US, in USD million (2019-2032)
  • Table 7: SER-109 Market Size in Germany, in USD million (2019-2032)
  • Table 8: SER-109 Market Size in France, in USD million (2019-2032)
  • Table 9: SER-109 Market Size in Italy, in USD million (2019-2032)
  • Table 10: SER-109 Market Size in Spain, in USD million (2019-2032)
  • Table 11: SER-109 Market Size in the UK, in USD million (2019-2032)
  • Table 12: SER-109 Market Size in Japan, in USD million (2019-2032)

List of Figures

  • Figure 1: SER-109 Market Size in the 7MM, USD million (2019-2032)
  • Figure 2: SER-109 Market Size in the United States, USD million (2019-2032)
  • Figure 3: SER-109 Market Size in Germany, USD million (2019-2032)
  • Figure 4: SER-109 Market Size in France, USD million (2019-2032)
  • Figure 5: SER-109 Market Size in Italy, USD million (2019-2032)
  • Figure 6: SER-109 Market Size in Spain, USD million (2019-2032)
  • Figure 7: SER-109 Market Size in the United Kingdom, USD million (2019-2032)
  • Figure 8: SER-109 Market Size in Japan, USD million (2019-2032)